101 related articles for article (PubMed ID: 22588881)
1. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Taylor M; Billiot F; Marty V; Rouffiac V; Cohen P; Tournay E; Opolon P; Louache F; Vassal G; Laplace-Builhé C; Vielh P; Soria JC; Farace F
Cancer Discov; 2012 May; 2(5):434-49. PubMed ID: 22588881
[TBL] [Abstract][Full Text] [Related]
2. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Shaked Y; Ciarrocchi A; Franco M; Lee CR; Man S; Cheung AM; Hicklin DJ; Chaplin D; Foster FS; Benezra R; Kerbel RS
Science; 2006 Sep; 313(5794):1785-7. PubMed ID: 16990548
[TBL] [Abstract][Full Text] [Related]
3. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Shaked Y; Tang T; Woloszynek J; Daenen LG; Man S; Xu P; Cai SR; Arbeit JM; Voest EE; Chaplin DJ; Smythe J; Harris A; Nathan P; Judson I; Rustin G; Bertolini F; Link DC; Kerbel RS
Cancer Res; 2009 Oct; 69(19):7524-8. PubMed ID: 19738066
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Redefining the target again: chemotherapeutics as vascular disrupting agents?
Gokmen-Polar Y; Miller KD
Cancer Cell; 2008 Sep; 14(3):195-6. PubMed ID: 18772108
[TBL] [Abstract][Full Text] [Related]
6. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function.
Jung SY; Choi JH; Kwon SM; Masuda H; Asahara T; Lee YM
J Cell Biochem; 2012 May; 113(5):1478-87. PubMed ID: 22298358
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
[TBL] [Abstract][Full Text] [Related]
8. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Shaked Y; Henke E; Roodhart JM; Mancuso P; Langenberg MH; Colleoni M; Daenen LG; Man S; Xu P; Emmenegger U; Tang T; Zhu Z; Witte L; Strieter RM; Bertolini F; Voest EE; Benezra R; Kerbel RS
Cancer Cell; 2008 Sep; 14(3):263-73. PubMed ID: 18772115
[TBL] [Abstract][Full Text] [Related]
9. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
10. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.
Shaked Y; Kerbel RS
Cancer Res; 2007 Aug; 67(15):7055-8. PubMed ID: 17671170
[TBL] [Abstract][Full Text] [Related]
12. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
14. Circulating endothelial cells as biomarkers in clinical oncology.
Mancuso P; Bertolini F
Microvasc Res; 2010 May; 79(3):224-8. PubMed ID: 20176038
[TBL] [Abstract][Full Text] [Related]
15. [Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].
Farace F; Bidart JM
Bull Cancer; 2007 Jul; 94 Spec No():S254-9. PubMed ID: 17846012
[TBL] [Abstract][Full Text] [Related]
16. Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies.
De Palma M; Nucera S
Cancer Discov; 2012 May; 2(5):395-7. PubMed ID: 22588875
[TBL] [Abstract][Full Text] [Related]
17. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
Shaked Y; Bertolini F; Man S; Rogers MS; Cervi D; Foutz T; Rawn K; Voskas D; Dumont DJ; Ben-David Y; Lawler J; Henkin J; Huber J; Hicklin DJ; D'Amato RJ; Kerbel RS
Cancer Cell; 2005 Jan; 7(1):101-11. PubMed ID: 15652753
[TBL] [Abstract][Full Text] [Related]
18. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
19. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
Bertolini F; Paul S; Mancuso P; Monestiroli S; Gobbi A; Shaked Y; Kerbel RS
Cancer Res; 2003 Aug; 63(15):4342-6. PubMed ID: 12907602
[TBL] [Abstract][Full Text] [Related]
20. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
Durrant D; Corwin F; Simoni D; Zhao M; Rudek MA; Salloum FN; Kukreja RC; Fatouros PP; Lee RM
Cancer Chemother Pharmacol; 2009 Jan; 63(2):191-200. PubMed ID: 18365199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
